LBRX (LB Pharmaceuticals) Stock Based Compensation: $6.12 Mil (TTM As of Mar. 2026)


LBRX LB Pharmaceuticals Inc LBRX
12 GF Score
Price $32.79
! 1 Warning Sign
View Full Analysis

What is LB Pharmaceuticals Stock Based Compensation?

LB Pharmaceuticals LBRX +0.51% 12 Stock Based Compensation is $6.12 Mil as of Mar. 2026. GuruFocus rates LBRX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

LB Pharmaceuticals's Stock Based Compensation for the three months ended in Mar. 2026 was $2.57 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $6.12 Mil.

LB Pharmaceuticals Stock Based Compensation Related Terms

LB Pharmaceuticals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for LB Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LB Pharmaceuticals Stock Based Compensation Chart

LB Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
0.43 0.30 3.16 4.19

LB Pharmaceuticals Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.34 0.88 2.34 2.57
LBRX
12GF Score
LB Pharmaceuticals Inc LBRX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LB Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.12 Mil.

What does a Stock Based Compensation of $6.12 Mil mean?
LB Pharmaceuticals (LBRX) has a Stock Based Compensation of $6.12 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for LB Pharmaceuticals and its competitors.
Is LB Pharmaceuticals' Stock Based Compensation too high?
LB Pharmaceuticals' current Stock Based Compensation is $6.12 Mil. Overall, LB Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LB Pharmaceuticals' Stock Based Compensation compare to MRVI and SLDB?
LB Pharmaceuticals' Stock Based Compensation of $6.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for LB Pharmaceuticals and its competitors. LB Pharmaceuticals's current Stock Based Compensation is $6.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LB Pharmaceuticals stock overvalued right now?
LB Pharmaceuticals (LBRX) has a current Stock Based Compensation of $6.12 Mil. The current Stock Based Compensation is $6.12 Mil. LB Pharmaceuticals' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For LB Pharmaceuticals (LBRX), the current Stock Based Compensation is $6.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LB Pharmaceuticals Business Description

Address One Pennsylvania Plaza, Suite 1025, New York, NY, USA, 10119
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
12GF Score

Get the complete analysis for LBRX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.79
Price